Loading...
•
Mar 31, 2021
Guardant Health Q1 2021 Earnings Report
Achieved revenue growth, driven by clinical tests, and launched Guardant Reveal for early-stage colorectal cancer.
Key Takeaways
Guardant Health reported a revenue of $78.7 million for the first quarter of 2021, a 17% increase compared to the corresponding period in 2020. The company launched Guardant Reveal and saw growth in clinical testing revenue, though it experienced a net loss of $109.7 million.
Revenue reached $78.7 million, a 17% increase year-over-year.
Clinical tests reported were 18,390, a 21% increase year-over-year.
Biopharmaceutical tests reported were 3,522, a 33% decrease year-over-year.
Guardant Reveal, a blood-only test for early-stage colorectal cancer, was successfully launched.
Revenue by Segment
Forward Guidance
Guardant Health expects full year 2021 revenue to be in the range of $360 million to $370 million, representing 26% to 29% growth over full year 2020. Clinical volumes for 2021 are expected to be greater than 90,000 tests, growing at least 42% over 2020.
Positive Outlook
- Full year 2021 revenue is expected to be in the range of $360 million to $370 million.
- Revenue growth of 26% to 29% is expected over full year 2020.
- Clinical volumes for 2021 are expected to be greater than 90,000 tests.
- Clinical volume growth of at least 42% is expected over 2020.
- Expansion of product portfolio.
Challenges Ahead
- Continuing impacts of COVID
- Increased operating expenses
- Increased net loss
- Increased adjusted EBITDA loss
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...